Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2014 Apr 24;73(6):1137–1146. doi: 10.1007/s00280-014-2447-3

Fig 4.

Fig 4

Fig 4

In vitro metabolism of EF-24. a) EF-24 (10 μM) was incubated with male CD2F1 mouse liver microsomes incubated for 15 minutes or human liver microsomes for 120 minutes in the presence or absence of NADPH. b) Ion chromatograms and daughter ion scans (inset) of putative hydroxylated metabolites with m/z 328 formed during incubation of 100 μM EF-24 with 3MC-pretreated male mouse liver microsomes. c) Ion chromatograms and daughter ion scans (inset) of putative hydroxylated metabolites with m/z 328 formed during incubation of 100 μM EF-24 with pooled human liver microsomes. d) Ion chromatograms and daughter ion scans (inset) of reduced EF-24 metabolites with m/z 314 following incubation of EF-24 with pooled human liver microsomes. e) Ion chromatograms and daughter ion scans (inset) of reduced EF-24 metabolites with m/z 316 following incubation of EF-24 with pooled human liver microsomes. f) Ion chromatogram and daughter ion scan (inset) of the unknown metabolite with m/z 298. g) Scheme of EF-24 metabolism. The asterisk denotes chiral center(s) produced in the metabolites